Who we are
The management team of NEO New Oncology
Corey R. Bouwman
Chief Executive Officer
Since autumn 2017, Corey R. Bouwman is the Chief Executive Officer at NEO New Oncology. Previously, he was responsible for Marketing, Sales, Healthcare Account Management and Strategic Market Development in the area Respiratory, Inflammation and Autoimmunity at the leading pharmaceutical company AstraZeneca as Vice President and member of the executive management. In 2009–2015, Corey held various executive management positions in Marketing, Sales, and business strategy of the pharmaceutical company Chiesi Group.
Chief Financial Officer
Together with Corey R. Bouwman, Christian Robrecht sits on the executive board of NEO New Oncology GmbH. Christian Robrecht has been with Siemens AG since 1992. After completing his degree in business management, Christian Robrecht was employed in various business units of the company and has been working in the Healthcare division since 2004. Since 2008, he is responsible for the sales and service business of the »West« region for Siemens Healthineers as a commercial manager in the German organization.
Dr. Johannes Heuckmann
Chief Scientific Officer
Johannes Heuckmann is your contact person for all scientific and technical questions on molecular genetic testing, data processing and data analysis. He is a biomedic who specializes in the field of functional cancer genomics. Johannes Heuckmann is the co-author of numerous international research papers and has been instrumental in developing our diagnostic NEO technology.
Dr. Lukas C. Heukamp (MB PhD)
Head of Medical Office
Lukas C. Heukamp is your contact person for all questions pertaining to diagnostics and interpretation of molecular genetic test results. He is a board certified pathologist as well as a trained molecular biologist. The focus of his long-standing research is the genomic stratification of patients for novel targeted therapeutic approaches. In his capacity as joint study director of the Lung Cancer Group Cologne, Lukas C. Heukamp was involved in the routine molecular pathological diagnosis of more than 3,000 cancer patients per year. He is the author of numerous peer-reviewed publications on targeted cancer therapies and molecular diagnostics.
Dr. Jutta Fritz, MBA
Head of Business Development
Jutta Fritz is your contact person pertaining to all questions regarding cooperation. She is a molecular biologist and for a number of years was responsible for the business development of the biotechnology company Kinaxo. Subsequently, she became Vice President of Business Development at Evotec AG, leading the proteomics division, which sought to elucidate the mode of action of oncological drugs. Jutta Fritz was responsible for numerous collaborations in the field of drug testing.
Dr. Sebastian Bartel
Head of Quality Management
Sebastian Bartel is the Head of Quality Management and Regulatory Affairs at NEO New Oncology. From 2013, Sebastian Bartel held a position as Quality Consultant at Siemens, supporting all Siemens Healthcare Business Units in questions regarding Quality Management and Auditing. Sebastian holds a PhD in Analytical Chemistry and has several years of experience in Bioanalytics and Medical Device Development in different companies.
Head of IT
Thomas Franz leads the Information Technology Department and is your contact for IT-related inquiries. With more than 20 years of expertise in heterogeneous IT environments, he has been instrumental in setting up the IT systems and processes in the company.
Dr. Christian Glöckner
Head of Research
Christian Glöckner is responsible for establishing and implementing new technologies at New Oncology. Upon completion of his doctorate on the function of DNA polymerases, he carried out research on precursor molecules for new drugs at The Scripps Research Institute, CA, USA. He then worked for many years as a scientist at Illumina, the world market leader in the field of next generation sequencing.
Sotirios Lakis MD, MSc
Head of Molecular Pathology
Sotirios Lakis is NEO New Oncology´s in-house pathologist. He is board certified with years´ experience in molecular diagnostic methods and he holds a master´s degree in Complex Systems and Networks from the Aristotle University of Thessaloniki. His doctorate project focuses on the impact of heterogeneity on ovarian cancer outcomes. As a cancer translational scientist, he has studied the clinical validity of multiple protein and genomic markers in breast, colorectal and lung cancers and he has co-authored numerous peer-reviewed publications.
Dr. Erika Mariotti
Head of Development
Erika Mariotti leads the Development Department consisting of highly specialized and experienced computational biologists, bioinformaticians, software developers and is responsible for the implementation of new analysis bioinformatic tools at NEO New Oncology. She joined the company in 2014 and was involved in setting up the routine bioinformatics data processing. Erika holds a PhD in biomedical engineering.
Dr. Roopika Menon
Head of Sample Operations & Analysis
Roopika Menon leads the Sample Operations & Analysis Department and is your contact for queries related to sample logistics, processing, and data analysis. She received her doctorate in the field of Molecular Biomedicine with a specialization in prostate cancer. With a strong publication record to her credit, she has been actively involved in setting up the diagnostic routines as well as overseeing and maintaining the day to day technical operations in the company.